Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-806 in KRAS G12D Mutated Advanced Solid Tumors
NCT07023731Phase 2Active, not recruiting
- Sponsor
- Arvinas
- Start
- May 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 2 trial of ARV-806 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), sponsored by Arvinas. Started May 2025; status: active, not recruiting.
02
Drugs
ARV-806
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07023731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023731.